Product information and disease description Product description Product information

Product comparison

10 evidence topics · 9 sources

Cardiovascular effects of tavapadon and other oral or transdermal dopamine agonists

Drug	Quoted route	Quoted mechanism	Quoted cardiovascular effect	Quoted status
Tavapadon	“Oral”	“D1/D5 partial agonist”	“Supine SBP reduction of −12 mmHg (versus 1.7 PBO); OH 6.5% versus 1.1% PBO (TEMPO-1); standing SBP drop of −8.6 mmHg (versus −0.8 PBO); OH 6% versus 1.2% PBO (TEMPO-3).”	“NDA filed (expected US approval in 2026)”
Pramipexole	“Oral”	“Non-ergot D2/D3 (D3 preferring)”	“OH: OR 1.65 (NS versus PBO); standing SBP −3 to 5 mmHg in PD.”	“Launched”
Ropinirole	“Oral”	“Non-ergot D2-like (D3>D2>>D4)”	“OH: OR 6.46 versus PBO; standing SBP −6 mmHg; HR +2–4 bpm in PD.”	“Launched”
Rotigotine	“Transdermal patch”	“Non-ergot nonselective DA agonist (D1, D2, D3)”	“OH ~18% in early PD versus PBO. Reduces nocturnal hypertension.”	“Launched”

Hypotension risk in relation to intrinsic activity

“Dopaminergic receptor agonism generally lowers blood pressure, with the magnitude of hypotension tracking with intrinsic activity: full orthosteric agonists (bromocriptine, ropirinole, apomorphine) carry the highest risk of orthostatic hypotension, and partial agonists (tavapadon) produce attenuated but clinically relevant hypotension.” (opens the source at this quote in a new tab)

Receptor mode of action of dopamine agonists used or in development for Parkinson's disease

Drug	Quoted mode of action	Quoted indication	Quoted phase of development
Pramipexole	“D2 agonist”	“PD motor symptoms and motor fluctuations”	“In clinical use”
Ropinirole	“D2 agonist”	“PD motor symptoms and motor fluctuations”	“In clinical use”
Rotigotine	“D2 > D1 agonist”	“PD motor symptoms and motor fluctuations”	“In clinical use”
Apomorphine continuous subcutaneous infusion	“D1 and D2 agonist”	“Motor fluctuations”	“In clinical use”
Tavapadon	“Selective D1 partial agonist”	“PD motor symptoms and motor fluctuations”	“Phase 3 completed”

Comparison with levodopa and D2/D3 agonists: mechanism, metabolism, half-life, and dosing frequency

Parameter	Tavapadon	Levodopa	D2/D3 agonists (e.g., pramipexole)
Mechanism of action	“Selective partial D1/D5 dopamine agonist”	“Non-selective dopamine precursor”	“D2/D3 full agonist”
Metabolism pathway	“Primarily CYP3A4”	“MAO-B and COMT”	“Various hepatic pathways”
Half-life	“~24 h”	“~60–90 min”	“5–12 h”
Dosing frequency	“Once daily”	“2–6 times daily”	“1–3 times daily”
Common side effects	“Nausea, headache, dizziness”	“Dyskinesias, severe on-off motor fluctuations”	“Impulsive behavior problems (e.g., gambling, hypersexual)”

Rationale for D1/D5 selectivity relative to D2/D3 agonists

“Furthermore, both levodopa and DAs are associated with a significant risk of AEs, many of which can be linked to strong, repeated stimulation of D2/D3 dopamine receptors.” (opens the source at this quote in a new tab)
“A commonly reported AE associated with currently used D2/D3 DAs is the risk of ICDs” (opens the source at this quote in a new tab)
“ICDs are reported in 17% of patients with PD taking D2/D3 DAs, a significantly greater rate of ICDs than observed with patients with PD not taking D2/D3 DAs (7%)” (opens the source at this quote in a new tab)

Pramipexole: receptor pharmacology, dosing frequency, half-life, and sleep-related warning

“Pramipexole is a non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes.” (opens the source at this quote in a new tab)
“Doses should be increased gradually from a starting dose of 0.375 mg/day given in three divided doses and should not be increased more frequently than every 5 to 7 days.” (opens the source at this quote in a new tab)
“Its terminal half-life is about 8 hours in young healthy volunteers and about 12 hours in elderly volunteers.” (opens the source at this quote in a new tab)
“Patients treated with pramipexole have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles which sometimes resulted in accidents.” (opens the source at this quote in a new tab)

Ropinirole: receptor pharmacology, dosing frequency, half-life, and sleep-related warning

“Ropinirole is a non-ergoline dopamine agonist. The precise mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, although it is thought to be related to its ability to stimulate dopamine D2 receptors within the caudate-putamen in the brain.” (opens the source at this quote in a new tab)
“The recommended starting dose of REQUIP for Parkinson’s disease is 0.25 mg 3 times daily.” (opens the source at this quote in a new tab)
“The clearance of ropinirole after oral administration is 47 L/h and its elimination half-life is approximately 6 hours.” (opens the source at this quote in a new tab)
“Patients treated with REQUIP have reported falling asleep while engaged in activities of daily living, including driving or operating machinery, which sometimes resulted in accidents.” (opens the source at this quote in a new tab)

Rotigotine: receptor pharmacology, dosing frequency, half-life, and sleep-related warning

“Rotigotine is a non-ergoline dopamine agonist. The precise mechanism of action of rotigotine as a treatment for Parkinson’s disease is unknown, although it is thought to be related to its ability to stimulate dopamine receptors within the caudate-putamen in the brain.” (opens the source at this quote in a new tab)
“NEUPRO should be applied once daily to clean, dry, and intact skin on the abdomen, thigh, hip, flank, shoulder, or upper arm.” (opens the source at this quote in a new tab)
“After removal of the patch, plasma levels decreased with a terminal half-life of 5 to 7 hours.” (opens the source at this quote in a new tab)
“Falling asleep during activities of daily living, including the operation of motor vehicles, and somnolence may occur. (5.2)” (opens the source at this quote in a new tab)

Tavapadon warnings and precautions for comparison with other dopamine agonists

“5.1 Hypotension/Orthostatic Hypotension 5.2 Impulse Control/Compulsive Behaviors 5.3 Hallucinations and Psychotic-like Behavior 5.4 Dyskinesia” (opens the prescribing information at this quote)
“The mean elimination half-life of tavapadon is approximately 25.5 hours.” (opens the prescribing information at this quote)

Receptor selectivity and adverse effects of tavapadon compared with D2 agonists in a commentary

“Among the currently marketed antiparkinsonian medications, L-DOPA (decarboxylated into dopamine) and apomorphine (a mixed D1/D2 agonist) are the only drugs that stimulate both receptor subtypes simultaneously. Conversely, all other antiparkinsonian dopamine agonists (eg, pramipexole, ropinirole, rotigotine, and others) are D2-selective, and no selective D1 agonists are available, highlighting a gap in our understanding of dopaminergic mechanisms and possibly in management of patients with Parkinson’s disease.” (opens the source at this quote in a new tab)
“The proportion of nausea and orthostatic hypotension in TEMPO-2 does not suggest a better profile on these peripheral side-effects than D2 agonists.” (opens the source at this quote in a new tab)
“The same applies to dyskinesia. Its incidence was low in TEMPO-2, comparable to D2 agonist trials, as expected in a short-term trial in levodopa-naive patients.” (opens the source at this quote in a new tab)
“On the other hand, somnolence was not a concern in TEMPO-2, as changes in Epworth Sleep Scale scores did not differ between groups, whereas sleepiness induced by D2 agonists is easily detected in small and short trials, even at low doses.” (opens the source at this quote in a new tab)